Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr2.70 SEK
Change Today 0.00 / 0.00%
Volume 400.0
As of 3:12 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

idl biotech ab- b shares (IDLB) Snapshot

Open
kr2.70
Previous Close
kr2.70
Day High
kr2.70
Day Low
kr2.70
52 Week High
02/19/15 - kr3.14
52 Week Low
10/10/14 - kr0.82
Market Cap
77.1M
Average Volume 10 Days
4.7K
EPS TTM
kr0.06
Shares Outstanding
27.3M
EX-Date
--
P/E TM
47.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for IDL BIOTECH AB- B SHARES (IDLB)

Related News

No related news articles were found.

idl biotech ab- b shares (IDLB) Related Businessweek News

No Related Businessweek News Found

idl biotech ab- b shares (IDLB) Details

IDL Biotech AB (publ), a diagnostic company, develops, produces, and markets in vitro diagnostic tests in the areas of oncology and bacteriology worldwide. Its oncology product includes MonoTotal, a tool for the management of patients with non-small cell lung cancer; TPAcyk, a quantitative serum monoclonal immunoassay reactive for the management of patients with epithelial cell carcinomas; TPS, a tumor activity marker used to support prognosis, treatment monitoring, and patient follow-up for various epithelial cancers, such as breast, colorectal, ovarian, and prostate cancers; and UBC, a non-invasive bladder cancer test. The company’s bacteriology product is TUBEX TF, an in vitro diagnostic test for the detection of acute typhoid fever. IDL Biotech AB (publ) distributes its products through a network of business partners primarily in Africa, Asia, Central America, Europe, and North and South America. The company was formerly known as AB IDL ImmunoDevelopLab and changed its name to IDL Biotech AB (publ) in 1998. IDL Biotech AB (publ) was founded in 1988 and is based in Bromma, Sweden.

Founded in 1988

idl biotech ab- b shares (IDLB) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: kr1.1M
Compensation as of Fiscal Year 2013.

idl biotech ab- b shares (IDLB) Key Developments

IDL Biotech AB (publ), Annual General Meeting, May 20, 2015

IDL Biotech AB (publ), Annual General Meeting, May 20, 2015.

IDL Biotech AB (publ) to Report Q1, 2015 Results on Apr 23, 2015

IDL Biotech AB (publ) announced that they will report Q1, 2015 results on Apr 23, 2015

IDL Biotech AB (publ) to Report Q1, 2014 Results on Apr 24, 2014

IDL Biotech AB (publ) announced that they will report Q1, 2014 results on Apr 24, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDLB:SS kr2.70 SEK 0.00

IDLB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDLB.
View Industry Companies
 

Industry Analysis

IDLB

Industry Average

Valuation IDLB Industry Range
Price/Earnings 51.5x
Price/Sales 2.8x
Price/Book 12.8x
Price/Cash Flow 31.7x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDL BIOTECH AB- B SHARES, please visit www.idl.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.